Display options
Share it on

BMC Clin Pathol. 2012 Aug 09;12:12. doi: 10.1186/1472-6890-12-12.

Diagnostic accuracy of monoclonal antibody based serum immunoglobulin free light chain immunoassays in myeloma cast nephropathy.

BMC clinical pathology

Colin A Hutchison, Paul Cockwell, Mark Cook

Affiliations

  1. Renal Institute of Birmingham, University Hospital and University of Birmingham, Birmingham, UK. [email protected].

PMID: 22873484 PMCID: PMC3507768 DOI: 10.1186/1472-6890-12-12

Abstract

BACKGROUND: The development of serum immunoassays for the measurement of immunoglobulin free light chains has led to a paradigm shift in the diagnosis, assessment and monitoring of patients with plasma cell dyscrasias. The impact of these immunoassays which employ polyclonal antibodies was most notable for those patients who were previously classified as non-secretory multiple myeloma. Recently new monoclonal antibody based assays have become available. The purpose of this study was to compare the diagnostic sensitivity of these new assays with those already in clinical practice.

METHODS: Sera from 30 patients who present with severe acute kidney injury and multiple myeloma were identified for analysis. A head to head comparison of the two commercially available free light chains assays was then undertaken to determine if their diagnostic sensitivity and specificity were comparable.

RESULTS: In this first assessment of the utility of these new assays, we found that one of 17 patients with a lambda monoclonal free light chain resulting in acute kidney injury were not identified and a further 12% of patients were wrongly classified as having levels below those associated with disease specific acute kidney injury.

CONCLUSION: These results suggest that caution should be applied to the use of new free light chain assays in the assessment of patients with a monoclonal gammopathy.

References

  1. Clin Chem. 2001 Apr;47(4):673-80 - PubMed
  2. Clin Chem. 2009 Aug;55(8):1517-22 - PubMed
  3. Br J Haematol. 2011 Jul;154(1):32-75 - PubMed
  4. J Am Soc Nephrol. 2011 Jun;22(6):1129-36 - PubMed
  5. Nephrol Dial Transplant. 2002 Nov;17(11):1909-13 - PubMed
  6. Clin J Am Soc Nephrol. 2008 Nov;3(6):1684-90 - PubMed
  7. J Am Soc Nephrol. 2007 Mar;18(3):886-95 - PubMed
  8. J Clin Invest. 1992 Feb;89(2):630-9 - PubMed
  9. J Clin Oncol. 2010 Feb 1;28(4):690-7 - PubMed
  10. Scand J Urol Nephrol. 1997 Feb;31(1):67-71 - PubMed
  11. Acta Crystallogr D Biol Crystallogr. 2002 May;58(Pt 5):815-23 - PubMed
  12. Artif Organs. 2008 Dec;32(12):910-7 - PubMed
  13. Blood. 2005 Aug 1;106(3):812-7 - PubMed
  14. Clin J Am Soc Nephrol. 2009 Apr;4(4):745-54 - PubMed
  15. N Engl J Med. 2011 Jun 16;364(24):2365-6 - PubMed
  16. Blood. 2008 Jan 15;111(2):785-9 - PubMed
  17. Leukemia. 2009 Feb;23(2):215-24 - PubMed
  18. Clin Chem. 2002 Sep;48(9):1437-44 - PubMed
  19. BMC Nephrol. 2008 Sep 22;9:11 - PubMed
  20. Clin Chem Lab Med. 2011 Aug;49(8):1323-32 - PubMed
  21. Leukemia. 2010 Jun;24(6):1121-7 - PubMed
  22. Lancet. 2010 May 15;375(9727):1721-8 - PubMed
  23. Kidney Int. 2008 Jun;73(11):1282-8 - PubMed
  24. Nephrol Dial Transplant. 2011 Apr;26(4):1438 - PubMed

Publication Types